Baird analyst Jeffrey Johnson raised the firm’s price target on Enovis to $70 from $67 and keeps an Outperform rating on the shares. The firm said they believe some investors are growing increasingly worried orthopedic backlogs have already depleted but theye think that’s dead wrong and they would be buying the weakness.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ENOV: